FINWIRES · TerminalLIVE
FINWIRES

ImmuneOnco Biopharm Invests HK$88 Million in Wealth Management Product

By

ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) agreed to invest HK$87.5 million in a wealth management product offered by Vital Ventures, according to a Wednesday Hong Kong bourse filing.

The cash management fund is expected to generate an annualized return of 1.5% to 4.5% and invests in assets including cash, bank deposits, certificates of deposit, and short-term U.S. Treasury bonds.

The company said the subscription will be funded by surplus cash reserves and is intended to improve capital utilization and generate additional income from idle funds.

Related Articles

Asia

Market Chatter: U.S. Government Holds Off on Adding Chinese Firms, Including DeepSeek, to Trade Blacklist

The U.S. government has held off on adding more than 100 Chinese companies, including artificial intelligence startup DeepSeek and memory chipmaker CXMT, on a trade blacklist to avoid raising tensions with Beijing, Reuters reported Wednesday.The firms were flagged for inclusion to the Commerce Department's Entity List due to national security risks.According to Reuters, the U.S. government believes DeepSeek supported China's military and intelligence operations and tried to illegally access advanced U.S. chips through Southeast Asian shell companies.CXMT was similarly designated as a Chinese military company by the Biden administration but is yet to be added to the list, the report said.DeepSeek and CXMT did not immediately respond to requests for comment by.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Shanghai Composite^SZSE
Asia

Zydus Lifesciences Completes Acquisition of US-Based Assertio Holdings

Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321), through its wholly-owned subsidiary, Zara Merger Sub, has completed the acquisition of all outstanding shares of common stock of NASDAQ-listed Assertio Holdings, according to a Tuesday filing to the Indian stock exchanges.The purchase was done at $23.50 per share of common stock of the U.S.-based specialty oncology pharmaceutical company Assertio, as part of a merger deal amounting to a total consideration of $166.3 million on a fully diluted basis.After the completion of the merger, Assertio will be the surviving entity, in which all shares of common stock not tendered into the offer will be cancelled and converted into the right to receive cash equal to the $23.50 offer price per common share.Assertio will become a wholly-owned subsidiary of the company, and its common stock will no longer be listed or traded on the Nasdaq, the statement said.

BOM:532321NSE:ZYDUSLIFE
Asia

Mapletree Pan Asia Commercial Trust Prices SG$200 Million Offering of Green Bonds

Mapletree Pan Asia Commercial Trust (SGX:N2IU) priced SG$200 million worth of 2.530% fixed-rate senior green bonds due in 2033, according to a Tuesday filing with the Singapore Exchange.Shares of the trust were up nearly 2% in Wednesday's trading.The debt securities will be issued on June 25. Deal proceeds used to finance or refinance eligible green projects.OCBC and United Overseas Bank are the joint lead managers and joint bookrunners.

SGX:N2IU